Keytruda could be a life-saving cancer treatment, but will Medicare cover the $11,000+ per infusion cost? The answer depends on your specific plan type, and the difference in out-of-pocket costs might shock you.
Key Takeaways
- Medicare Part B covers Keytruda infusions after meeting the $257 deductible, treating it as outpatient medical care rather than a prescription drug.
- Out-of-pocket costs vary significantly by Medicare plan type – Original Medicare beneficiaries typically pay $1,300-$2,100 per infusion, while 38% of Medicare Advantage members pay nothing.
- Financial assistance programs can dramatically reduce costs – Medicaid recipients often pay just $4-$8 per infusion, and manufacturer programs offer additional support.
- Pre-authorization is required to avoid coverage surprises, especially for off-label uses or dosages above FDA guidelines.
Keytruda, also known as pembrolizumab, represents a breakthrough in cancer immunotherapy treatment. This PD-1 inhibitor helps boost the immune system’s ability to attack cancer cells, offering hope for patients with lung, breast, skin, and other cancers. For Medicare beneficiaries considering this potentially life-saving treatment, understanding coverage details becomes vital for making informed healthcare decisions.
Medicare Part B Covers Keytruda After $257 Deductible
Medicare Part B covers Keytruda infusions because the medication requires intravenous administration by healthcare professionals in clinical settings. Unlike oral medications covered under Part D prescription plans, infusion therapies fall under Part B’s outpatient medical services coverage.
The 2025 Medicare Part B deductible stands at $257, which beneficiaries must meet before coverage begins. Once this deductible is satisfied, Medicare covers 80% of the approved treatment costs, leaving patients responsible for the remaining 20% coinsurance. Understanding Medicare coverage options helps beneficiaries navigate these healthcare decisions with greater confidence.
The list price for a single 200mg Keytruda dose reaches approximately $11,337.36, according to manufacturer data. However, Medicare’s negotiated rates typically result in significantly lower costs than these published prices, making the treatment more accessible for covered beneficiaries.
Your Out-of-Pocket Costs by Medicare Plan Type
Understanding how different Medicare plan types handle Keytruda coverage helps patients anticipate their financial responsibilities and make informed treatment decisions.
1. Original Medicare: You Pay 20% After Deductible ($1,300-$2,100)
With Original Medicare Parts A and B, beneficiaries face predictable but potentially substantial costs. After meeting the $257 Part B deductible, patients pay 20% coinsurance for each infusion. Based on manufacturer data, the average Original Medicare beneficiary without supplemental coverage pays between $1,300 and $2,100 per Keytruda treatment after meeting their deductible.
These costs can accumulate quickly, as Keytruda treatments typically occur every three weeks for extended periods. The financial burden often motivates beneficiaries to seek supplemental insurance options or financial assistance programs to manage expenses.
2. Medicare Advantage: Costs Vary by Plan
Medicare Advantage plans must provide at least the same coverage as Original Medicare, but out-of-pocket costs vary dramatically between plans and regions. According to manufacturer data, approximately 38% of Medicare Advantage plan members have no out-of-pocket costs for Keytruda infusions.
Among Medicare Advantage members who do face costs, about 80% pay between $0.01 and $925 per infusion after meeting their plan’s deductible. This wide variation reflects the diverse benefit structures across different Medicare Advantage plans, making plan comparison necessary for cancer patients.
3. Medigap Plans Can Eliminate Your Coinsurance
Medigap supplemental insurance plans can significantly reduce or eliminate out-of-pocket costs for Keytruda treatments. Plans that cover Part B coinsurance – including Plans A, B, C, D, F, G, and M – can reduce patient costs to zero after the deductible is met. Note that Medigap plans C and F are no longer available to newly eligible enrollees since 2020.
High-deductible Medigap plans require beneficiaries to spend more than $2,870 before coverage begins, but once this threshold is reached, coinsurance costs are typically covered. Plans K and L offer partial coinsurance coverage, with beneficiaries paying 50% and 25% respectively of the coinsurance amount.
When Medicare Won’t Cover Keytruda
While Medicare generally covers Keytruda for approved indications, certain circumstances can result in coverage denials that leave patients facing full treatment costs.
Off-Label Use for Unapproved Conditions
Medicare typically covers Keytruda only for FDA-approved indications, which include specific types of melanoma, lung cancer, bladder cancer, and other conditions outlined in the drug’s official labeling. When physicians prescribe Keytruda for off-label uses – treating conditions not specifically approved by the FDA – Medicare may deny coverage.
Patients seeking off-label treatment should work closely with their healthcare providers to document medical necessity and consider appeal processes if initial coverage requests are denied.
Dosage Above FDA Guidelines
Medicare may decline coverage when physicians prescribe Keytruda dosages that exceed FDA-approved guidelines. The standard dosing regimens are carefully established through clinical trials, and deviations from these protocols can trigger coverage reviews.
Healthcare providers must justify any dosage modifications with detailed medical documentation to maintain Medicare coverage eligibility.
Financial Assistance Programs for Additional Help
Multiple assistance programs exist to help Medicare beneficiaries manage Keytruda costs, particularly for those facing financial hardship.
Medicaid Can Reduce Costs to $4-$8 Per Infusion
Medicare beneficiaries who also qualify for Medicaid – known as “dual eligibles” – often face dramatically reduced out-of-pocket costs. According to manufacturer data, most Medicaid recipients pay between $4 and $8 per Keytruda infusion, making this life-saving treatment accessible regardless of income level.
Medicaid eligibility depends on income and asset requirements that vary by state. Beneficiaries should contact their state Medicaid office or visit medicaid.gov to determine qualification status.
Patient Assistance Programs for Commercial Insurance
The Merck Access Program offers financial assistance for eligible patients, including copay assistance cards and free medication for qualifying individuals without adequate insurance coverage. This manufacturer-sponsored program helps bridge coverage gaps and reduce financial barriers to treatment.
Patients can apply for assistance by calling 855-257-3932 or visiting the program’s dedicated website to complete eligibility screenings and application processes.
Other Support Organizations
Organizations like Simplefill specialize in connecting patients with various assistance programs to manage high medication costs. These services help patients work through the complex landscape of patient assistance programs, charitable foundations, and state-specific support options.
Cancer support organizations and hospital social workers can also provide valuable guidance on accessing financial assistance resources and working through insurance challenges.
Get Pre-Authorization to Avoid Coverage Surprises
Obtaining pre-authorization before beginning Keytruda treatment helps prevent unexpected coverage denials and financial surprises. Healthcare providers typically handle prior authorization requests, submitting detailed medical documentation to support treatment necessity.
The pre-authorization process involves reviewing patient medical history, cancer diagnosis details, previous treatment attempts, and expected treatment outcomes. This documentation helps Medicare determine whether Keytruda represents a medically necessary and appropriate treatment option.
Patients should request written confirmation of coverage decisions and understand their appeal rights if initial authorization requests are denied. Having clear documentation protects against billing disputes and ensures uninterrupted treatment access.
Working with experienced healthcare providers who understand Medicare requirements can streamline the authorization process and improve approval chances for necessary cancer treatments.
Page content independently curated and maintained by David W. Bynon, Medicare Technical Operator, using a standardized, data-driven methodology designed for accurate, non-commercial Medicare plan interpretation and resolution.